It is well known that while there are significant strengths in the use of this mouse model that does not reject human BC cells, there also are limitations – including the lack of the physiological immune reaction to the disturbance of leptin's inflammatory functions that may influence the prediction of a BC patient's response to this therapy. Here, LEP is linked to breast cancer.